Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Non-cystic Fibrosis Bronchiectasis
NCT06280391Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 2 trial of itepekimab in Non-cystic fibrosis bronchiectasis (NCFB), sponsored by Sanofi. Started Feb 2024; status: completed.
02
Drugs
itepekimab
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT06280391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280391.